AC Immune (NASDAQ:ACIU) Stock Crosses Below 50 Day Moving Average – Time to Sell?

AC Immune (NASDAQ:ACIU) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.80 and traded as low as $2.31. AC Immune shares last traded at $2.37, with a volume of 124,100 shares trading hands.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Jefferies Financial Group reiterated a “buy” rating and issued a $7.00 target price on shares of AC Immune in a research note on Friday, March 13th. Finally, BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Monday, May 4th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.50.

AC Immune Stock Performance

The company has a market capitalization of $244.25 million, a PE ratio of -2.93 and a beta of 1.59. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $2.77 and a two-hundred day moving average price of $2.97.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $0.33 million. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%. Analysts predict that AC Immune will post -0.84 EPS for the current fiscal year.

Insider Activity

In other news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the transaction, the chief executive officer directly owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On AC Immune

Several hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the period. Susquehanna International Group LLP purchased a new position in shares of AC Immune during the 3rd quarter valued at $63,000. Marshall Wace LLP purchased a new position in shares of AC Immune during the 4th quarter valued at $586,000. Finally, Acadian Asset Management LLC increased its holdings in shares of AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after purchasing an additional 172,796 shares during the period. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.